Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience.
| Publicado en: | Journal of Clinical Oncology Vol. 41; pp. 9572 - 9573 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2023 Supplement 16
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Descripción no disponible. |